Director David C. Habiger purchased 2,200 shares for $125k, marking the largest purchase of his career. This move comes as the stock has crashed nearly 45% over the last year, potentially signaling a bottom in the valuation.
Price context
The stock is up 6.66% over the last five days but remains down 23.4% over the last three months and 45.4% over the past year. It is currently trading 8.76% above its 52-week low of $52.53 and 47.83% below its 52-week high of $109.50.
Catalysts to watch
- •Boston Scientific reported positive pivotal trial results for its SEISMIQ 4CE Coronary Intravascular Lithotripsy Catheter on May 20, supporting a regulatory submission.
- •Management highlighted WATCHMAN's 19% growth on May 26, aiming to expand the addressable market from 5M to 20M patients.
- •The stock is down 13% since the last earnings report 30 days ago, setting up the next print for a potential rebound.
Risks
- •BofA cut the price target to $68 from $105 on May 26, citing worries for the medtech sector.
- •The company recalled LUX-Dx II arrhythmia detector devices on May 26 following FDA enforcement reports citing data collection failures.
AI-generated context from public data. Not investment advice. Verify before trading.